Roger Jeffs Sells 22,343 Shares of Liquidia Co. (NASDAQ:LQDA) Stock

Liquidia Co. (NASDAQ:LQDA) CEO Roger Jeffs sold 22,343 shares of the business’s stock in a transaction on Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total transaction of $263,200.54. Following the transaction, the chief executive officer now directly owns 1,019,177 shares of the company’s stock, valued at approximately $12,005,905.06. This trade represents a 2.15 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Liquidia Trading Up 6.9 %

Shares of Liquidia stock opened at $12.14 on Thursday. The company’s 50-day moving average price is $11.23 and its two-hundred day moving average price is $11.02. Liquidia Co. has a 52 week low of $8.26 and a 52 week high of $16.99. The stock has a market cap of $1.03 billion, a PE ratio of -7.45 and a beta of 0.23.

Analysts Set New Price Targets

LQDA has been the subject of several analyst reports. Lifesci Capital initiated coverage on shares of Liquidia in a report on Thursday, October 3rd. They set an “outperform” rating and a $30.00 price target for the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $19.00 price objective on shares of Liquidia in a report on Thursday, January 9th. Scotiabank assumed coverage on shares of Liquidia in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $30.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and issued a $29.00 price objective on shares of Liquidia in a report on Thursday, November 14th. Finally, Wells Fargo & Company assumed coverage on shares of Liquidia in a report on Friday, December 20th. They issued an “overweight” rating and a $20.00 price objective for the company. One analyst has rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $25.38.

Institutional Investors Weigh In On Liquidia

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Whitcomb & Hess Inc. raised its position in Liquidia by 10.2% in the third quarter. Whitcomb & Hess Inc. now owns 11,599 shares of the company’s stock worth $116,000 after acquiring an additional 1,074 shares in the last quarter. Arizona State Retirement System raised its position in Liquidia by 10.7% in the second quarter. Arizona State Retirement System now owns 13,842 shares of the company’s stock worth $166,000 after acquiring an additional 1,341 shares in the last quarter. Quest Partners LLC bought a new stake in Liquidia in the second quarter worth about $27,000. Profund Advisors LLC raised its holdings in Liquidia by 31.6% during the 2nd quarter. Profund Advisors LLC now owns 14,434 shares of the company’s stock worth $173,000 after buying an additional 3,466 shares during the period. Finally, DMC Group LLC raised its holdings in Liquidia by 36.7% during the 3rd quarter. DMC Group LLC now owns 13,883 shares of the company’s stock worth $139,000 after buying an additional 3,725 shares during the period. 64.54% of the stock is currently owned by institutional investors.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).